Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03430466
What this trial is testing

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Kyoto Breast Cancer Research Network 1
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Large-scale testing (Phase 3)Study completedNCT02003209
What this trial is testing

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Who this might be right for
HER2-Positive Breast CarcinomaHormone Receptor-Positive Breast CarcinomaStage IB Breast Cancer AJCC v7+5 more
National Cancer Institute (NCI) 315
Testing effectiveness (Phase 2)Study completedNCT03671330
What this trial is testing

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 327
Not applicableStudy completedNCT03099200
What this trial is testing

An Observational Study Evaluating the Productivity and Health-Related Quality of Life of People With HER2 Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 300
Early research (Phase 1)Looking for participantsNCT05504707
What this trial is testing

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04721977
What this trial is testing

Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

Who this might be right for
Breast Cancer
Pfizer 66
Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Testing effectiveness (Phase 2)Looking for participantsNCT06348134
What this trial is testing

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHER2-positive Breast CancerBreast Cancer
University of Chicago 74
Testing effectiveness (Phase 2)Looking for participantsNCT07558733
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Who this might be right for
HR+ HER2- Breast Cancer
Faeth Therapeutics 32
Large-scale testing (Phase 3)Ended earlyNCT02340221
What this trial is testing

Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 631
Large-scale testing (Phase 3)Not Yet RecruitingNCT07393321
What this trial is testing

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical 210
Not applicableUnknownNCT05982626
What this trial is testing

Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Huashan Hospital 10
Not applicableLooking for participantsNCT07073755
What this trial is testing

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

Who this might be right for
Metastatic Breast CancerDrug ResistanceHormone Receptor-Positive Breast Cancer+3 more
Hunan Cancer Hospital 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT02942355
What this trial is testing

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

Who this might be right for
Female Breast CarcinomaBreast Cancer
Wake Forest University Health Sciences 40
Not applicableStudy completedNCT01433926
What this trial is testing

Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years

Who this might be right for
HER-2 Positive Breast Cancer
Asociación para el Progreso de la Oncología en Málaga 114
Early research (Phase 1)Ended earlyNCT01281163
What this trial is testing

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Positive+4 more
National Cancer Institute (NCI) 4
Not applicableStudy completedNCT06386263
What this trial is testing

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
AstraZeneca 22
Not applicableLooking for participantsNCT07597993
What this trial is testing

BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Who this might be right for
Breast Cancer
AstraZeneca 109
Not applicableLooking for participantsNCT06340516
What this trial is testing

NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity

Who this might be right for
CardiotoxicityBreast CancerTreatment Side Effects
Vastra Gotaland Region 700
Next Page